« JuneauEmpire.com: Local: Rush is on as dividend deadline drops 03/31/05 | Main | What to Tell the Boss After a Diagnosis »

Multiple Sclerosis - TYSABRI� Update

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that their ongoing safety evaluation of TYSABRI� (natalizumab) has led to a previously diagnosed case of malignant astrocytoma being reassessed as progressive multifocal leukoencephalopathy (PML), in a patient in an open label Crohn's disease clinical trial.

More here.

April 2, 2005 in tysabri | Permalink

Comments